These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12055848)

  • 1. Mechanisms of pathogenesis: differences amongst Leishmania species.
    Colmenares M; Kar S; Goldsmith-Pestana K; McMahon-Pratt D
    Trans R Soc Trop Med Hyg; 2002 Apr; 96 Suppl 1():S3-7. PubMed ID: 12055848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunopathogenesis of Leishmania infections].
    Yurdakul P
    Mikrobiyol Bul; 2005 Jul; 39(3):363-81. PubMed ID: 16358498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease?
    McMahon-Pratt D; Alexander J
    Immunol Rev; 2004 Oct; 201():206-24. PubMed ID: 15361243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffuse cutaneous leishmaniasis in Ethiopia. 3. Immunological studies. IV. Pathogenesis of diffuse cutaneous leishmaniasis.
    Bryceson AD
    Trans R Soc Trop Med Hyg; 1970; 64(3):380-93. PubMed ID: 4195254
    [No Abstract]   [Full Text] [Related]  

  • 5. Animal models for the analysis of immune responses to leishmaniasis.
    Sacks DL; Melby PC
    Curr Protoc Immunol; 2015 Feb; 108():19.2.1-19.2.24. PubMed ID: 25640990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous Manifestations of Human and Murine Leishmaniasis.
    Scorza BM; Carvalho EM; Wilson ME
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to master the host immune system? Leishmania parasites have the solutions!
    Rossi M; Fasel N
    Int Immunol; 2018 Mar; 30(3):103-111. PubMed ID: 29294040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Host and parasite factors influencing the expression of cutaneous leishmaniasis.
    Sher A; Sacks DL; Scott PA
    Ciba Found Symp; 1983; 99():174-89. PubMed ID: 6227463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil: a review.
    Silveira FT; Lainson R; Corbett CE
    Mem Inst Oswaldo Cruz; 2004 May; 99(3):239-51. PubMed ID: 15273794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine candidates for leishmaniasis: a review.
    Nagill R; Kaur S
    Int Immunopharmacol; 2011 Oct; 11(10):1464-88. PubMed ID: 21616175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunopathogenic competences of Leishmania (V.) braziliensis and L. (L.) amazonensis in American cutaneous leishmaniasis.
    Silveira FT; Lainson R; De Castro Gomes CM; Laurenti MD; Corbett CE
    Parasite Immunol; 2009 Aug; 31(8):423-31. PubMed ID: 19646206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemokines in host-parasite interactions in leishmaniasis.
    Teixeira MJ; Teixeira CR; Andrade BB; Barral-Netto M; Barral A
    Trends Parasitol; 2006 Jan; 22(1):32-40. PubMed ID: 16310413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Further Evidence of an Association between the Presence of Leishmania RNA Virus 1 and the Mucosal Manifestations in Tegumentary Leishmaniasis Patients.
    Cantanhêde LM; da Silva Júnior CF; Ito MM; Felipin KP; Nicolete R; Salcedo JM; Porrozzi R; Cupolillo E; Ferreira Rde G
    PLoS Negl Trop Dis; 2015; 9(9):e0004079. PubMed ID: 26372217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of host genetics in leishmaniasis.
    Sakthianandeswaren A; Foote SJ; Handman E
    Trends Parasitol; 2009 Aug; 25(8):383-91. PubMed ID: 19617002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex-Related Differences in Immune Response and Symptomatic Manifestations to Infection with
    Lockard RD; Wilson ME; Rodríguez NE
    J Immunol Res; 2019; 2019():4103819. PubMed ID: 30756088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview on Leishmania (Mundinia) enriettii: biology, immunopathology, LRV and extracellular vesicles during the host-parasite interaction.
    Paranaiba LF; Pinheiro LJ; Macedo DH; Menezes-Neto A; Torrecilhas AC; Tafuri WL; Soares RP
    Parasitology; 2018 Sep; 145(10):1265-1273. PubMed ID: 29223169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A historical review of the role of cytokines involved in leishmaniasis.
    Mirzaei A; Maleki M; Masoumi E; Maspi N
    Cytokine; 2021 Sep; 145():155297. PubMed ID: 32972825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue damage and immunity in cutaneous leishmaniasis.
    Nylén S; Eidsmo L
    Parasite Immunol; 2012 Dec; 34(12):551-61. PubMed ID: 23009296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.
    Aguilar-Be I; da Silva Zardo R; Paraguai de Souza E; Borja-Cabrera GP; Rosado-Vallado M; Mut-Martin M; García-Miss Mdel R; Palatnik de Sousa CB; Dumonteil E
    Infect Immun; 2005 Feb; 73(2):812-9. PubMed ID: 15664920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.
    Salay G; Dorta ML; Santos NM; Mortara RA; Brodskyn C; Oliveira CI; Barbiéri CL; Rodrigues MM
    Clin Vaccine Immunol; 2007 Sep; 14(9):1173-81. PubMed ID: 17626159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.